Chemelex Makes Minority Investment in Algo8 to Advance AI-Driven Manufacturing
16.4.2026 15:00:00 CEST | Business Wire | Press Release
Chemelex, a global leader in electric thermal and sensing solutions, announced today that it has made a minority investment in Algo8, an industrial artificial intelligence (AI) company, to accelerate the use of AI in manufacturing.
The investment will support further development of Algo8’s technology while enabling Chemelex to enhance its manufacturing processes and improve productivity, while continuing to deliver high product quality to customers.
Chemelex Chief Executive Officer David Prystash will join Algo8’s Board of Advisors.
The partnership is built on existing commercial engagement and underscores Chemelex’s focus on applying advanced technologies to strengthen operational performance and supply reliability across its global manufacturing footprint.
Algo8 develops Plantbrain, a proprietary AI software that integrates data across industrial systems to generate predictive and prescriptive insights, helping manufacturers optimize operations, reduce downtime, and improve decision-making.
Chemelex deploys Algo8’s technology across its operations to improve process consistency, increase manufacturing efficiency, enable faster, data-driven decision-making and enhance supply reliability for customers.
For Algo8, the investment provides capital to accelerate product development and access to Chemelex’s global manufacturing base, supporting broader deployment of its platform in industrial environments.
“Investing in advanced technologies is central to how we continue to lead in manufacturing excellence,” said David Prystash, CEO of Chemelex. “Algo8’s approach to industrial AI aligns with our commitment to delivering high-quality, reliable products. Integrating these capabilities into our operations will enhance productivity, improve consistency, and strengthen our ability to meet customer demand.”
Nandan Mishra, CEO and Co-Founder of Algo8, said: “Partnering with Chemelex allows us to accelerate development of our platform and scale its deployment across global manufacturing environments. Together, we aim to deliver measurable performance improvements through AI-driven solutions.”
About Chemelex
Chemelex is a global leader in electric thermal and sensing solutions, protecting the world’s critical processes, places and people. With over 50 years of innovation and a commitment to excellence, we develop solutions that ensure safety, reliability, and efficiency in diverse environments – from industrial plants and data centers to people’s homes.
Chemelex trusted brands include Raychem, Tracer, Pyrotenax, and Nuheat, all enabling the world to move forward with confidence.
For more information, visit www.chemelex.com.
About Algo8
Algo8 is an industrial AI company developing software platforms for manufacturing and industrial environments. Its technology integrates data across systems to deliver predictive and prescriptive insights that improve efficiency, productivity, and operational performance.
The company operates across North America, Europe, the Middle East, and Asia.
For more information, visit www.algo8.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260416344462/en/
Contacts
Media Contact
Chemelex
Lowie Van Rymenant
VP Marketing
Lowie.vanrymenant@chemelex.com
+32 (478) 278 893
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press Release
The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen Chupka, executive vice president, National Association of Broadcasters. “This year’s Show reflects the accelerating pace of innovation and
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press Release
The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen Chupka, executive vice president, National Association of Broadcasters. “This year’s Show reflects the accelerating pace of innovation and
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press Release
The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit the health of the population as a whole taking into account both users of tobacco products and persons who do not currently use tobacco products. “As the only company to have successfully secured and maintained MRTP authorizations for heated tobacco products in the U.S., we are confident that our science-based alternatives can help adult smokers transition away from combustible cigarettes,” said Stacey Kenned
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom